Intrarosa (prasterone) is a small molecule pharmaceutical. Prasterone was first approved as Intrarosa on 2016-11-16. It is used to treat adrenal insufficiency, dyspareunia, lupus vulgaris, and sexual and gender disorders in the USA. It has been approved in Europe to treat postmenopause. It is known to target glycine receptor subunit alpha-1, glycine receptor subunit alpha-2, glycine receptor subunit alpha-3, and glycine receptor subunit beta. Intrarosa's patents are valid until 2031-03-19 (FDA).
|Indication||adrenal insufficiency, dyspareunia, lupus vulgaris, postmenopause, sexual and gender disorders|
|Drug Class||Steroids (androgens, anabolics)|